PCSK9 Inhibitor class drugs

2 results

  • praluent

    (alirocumab)
    Regeneron Pharmaceuticals, Inc.
    PRALUENT® is indicated to reduce the risk of myocardial infarction, stroke, and unstable angina in adults with cardiovascular disease. It also lowers LDL-C in adults with primary hyperlipidemia or familial hypercholesterolemia and in pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia.
    Medication Details
    Drug Interactions

  • repatha

    (Evolocumab)
    Amgen USA Inc.
    REPATHA is indicated for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and as an adjunct to diet and other therapies to lower LDL cholesterol in adults and pediatric patients (ages 10+) with primary hyperlipidemia, heterozygous, or homozygous familial hypercholesterolemia.
    Medication Details
    Drug Interactions